Gilead Sciences (NASDAQ:GILD) Price Target Raised to $170.00 at Wolfe Research

Gilead Sciences (NASDAQ:GILD) had its price objective hoisted by Wolfe Research from $155.00 to $170.00 in a research report released on Thursday morning,MarketScreener reports. Wolfe Research currently has an outperform rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on GILD. BMO Capital Markets increased their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, January 26th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a research note on Wednesday. TD Cowen increased their target price on shares of Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Finally, Truist Financial upped their price objective on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday. Twenty-three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $152.42.

Gilead Sciences Stock Down 2.6%

GILD stock opened at $151.81 on Thursday. Gilead Sciences has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The firm has a 50-day simple moving average of $129.59 and a 200-day simple moving average of $121.98. The stock has a market capitalization of $188.35 billion, a P/E ratio of 22.42, a P/E/G ratio of 0.81 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period in the previous year, the firm posted $1.90 EPS. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is currently 46.68%.

Insider Activity at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the insider owned 103,221 shares in the company, valued at approximately $12,831,402.51. This trade represents a 2.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 319,391 shares of company stock valued at $44,141,101 over the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently made changes to their positions in the stock. Empire Financial Management Company LLC boosted its position in shares of Gilead Sciences by 15.4% during the 4th quarter. Empire Financial Management Company LLC now owns 3,000 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 400 shares during the period. Laurel Oak Wealth Management LLC acquired a new position in Gilead Sciences during the fourth quarter worth $371,000. Northwest & Ethical Investments L.P. boosted its position in shares of Gilead Sciences by 2.9% during the fourth quarter. Northwest & Ethical Investments L.P. now owns 328,207 shares of the biopharmaceutical company’s stock worth $40,286,000 after buying an additional 9,388 shares during the period. Saiph Capital LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $203,000. Finally, Rossby Financial LCC grew its stake in shares of Gilead Sciences by 12.2% in the fourth quarter. Rossby Financial LCC now owns 926 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 101 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat consensus — revenue and EPS topped estimates, driven by HIV and liver‑disease portfolio strength and early traction for new products; this underpins analyst bullishness and longer‑term revenue visibility. GILD’s Q4 Earnings Beat
• Positive Sentiment: Big wave of analyst price‑target increases and buy/outperform notes (examples: Morgan Stanley $171, Scotiabank $177, Needham/Wolfe $170, Wells Fargo & JPMorgan mid‑$160s) — brokers cite HIV momentum, margin expansion and product pipeline (Yeztugo, Yescarta) as reasons to raise targets. Analyst Coverage Summary
• Positive Sentiment: Dividend increase announced — quarterly dividend up to $0.82 (3.8% raise), supporting income investor appeal and signaling management confidence in cash flow.
• Neutral Sentiment: Earnings call / transcripts published (multiple outlets) — useful for detail on guidance assumptions, product rollouts and cost/margin outlook but neutral until investors parse management commentary. Earnings Call Transcript
• Neutral Sentiment: Yescarta label expansion and new product commentary appear in coverage — potential medium‑term upside if uptake meets expectations; currently a pipeline/progression read‑through. Yescarta & Dividend Coverage
• Neutral Sentiment: Short‑interest notes in data feeds show anomalous 0 shares / NaN changes — not meaningful evidence of a short squeeze or new bearish positioning based on available figures.
• Negative Sentiment: FY‑2026 guidance came in below some Street expectations — management’s outlook tempered the post‑earnings rally and is the principal reason for the intraday/extended‑session pullback despite the beat. Guidance / Shares Dip
• Negative Sentiment: At least one broker adjustment (Royal Bank of Canada) shows a lower relative price target in published feeds despite a PT raise vs. prior internal note — highlights disagreement among analysts on near‑term valuation and reinforces guidance‑driven uncertainty. RBC / Ticker Report

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.